Company Forte Biosciences, Inc.

Equities

FBRX

US34962G1094

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.739 ^USD	+2.65%		-5.26%	-10.06%

Mar. 18	Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 05	Camac Partners Provides Information to Shareholders	CI

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Companyâs FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Companyâs subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

Number of employees: 9

Managers	Title	Age	Since
Paul Wagner CEO	Chief Executive Officer	53	16-12-31
Anthony Riley DFI	Director of Finance/CFO	57	20-02-29
Christopher Roenfeldt COO	Chief Operating Officer	-	20-09-30
Steven J. Ruhl CTO	Chief Tech/Sci/R&D Officer	-	21-06-30

Members of the board	Title	Age	Since
David Gryska BRD	Director/Board Member	68	23-01-09
Steven Kornfeld BRD	Director/Board Member	56	20-05-31
Stephen Doberstein BRD	Director/Board Member	65	22-05-11
Barbara Finck BRD	Director/Board Member	77	22-03-15
Paul Wagner CEO	Chief Executive Officer	53	16-12-31
Donald Williams BRD	Director/Board Member	65	20-05-31
Scott Brun BRD	Director/Board Member	56	22-11-09
Lawrence Eichenfield BRD	Director/Board Member	66	20-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,394,882	29,153,718 ( 80.10 %)	0	80.10 %

Name	Equities	%	Valuation
Tybourne Capital Management (HK) Ltd. 9.959 %	3,624,548	9.959 %	3 M $
Perceptive Advisors LLC 8.972 %	3,265,359	8.972 %	2 M $
Maples Corporate Services (BVI) Ltd. 8.536 %	3,106,756	8.536 %	2 M $
BVF, Inc. 8.194 %	2,982,105	8.194 %	2 M $
Cable Car Capital LLC 5.583 %	2,031,987	5.583 %	1 M $
Paul Wagner 5.163 %	1,879,174	5.163 %	1 M $
Fred Alger Management LLC (13f Subfiler) 5.053 %	1,838,965	5.053 %	1 M $
Farallon Capital Management LLC 4.974 %	1,810,455	4.974 %	1 M $
BML Capital Management LLC 4.841 %	1,761,702	4.841 %	1 M $
BML Capital Management LLC 4.841 %	1,761,702	4.841 %	1 M $

Forte Biosciences, Inc.

3060 Pegasus Park Drive Building 6

75247, Dallas

http://www.fortebiorx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.739 USD

Average target price

2.875 USD

Spread / Average Target

+289.04%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
FORTE BIOSCIENCES, INC.	-10.06%	26.2M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs